<p>随着全球市场表现不一，日本股市下跌，而中国制造业部门显示出适度改善，投资者越来越关注亚洲股票中的潜在机会。在这种环境下，识别被低估的股票可以是一项战略性举措，因为这些投资在市场条件稳定或改善时可能提供显著的上行潜力。</p>
<h3>基于现金流的亚洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>药明 XDC 开曼（SEHK:2268）</td>
<td>HK$68.50</td>
<td>HK$135.26</td>
<td>49.4%</td>
</tr>
<tr>
<td>Visional（TSE:4194）</td>
<td>¥10040.00</td>
<td>¥19790.82</td>
<td>49.3%</td>
</tr>
<tr>
<td>苏州泽璟生物制药（SHSE:688266）</td>
<td>CN¥99.90</td>
<td>CN¥199.49</td>
<td>49.9%</td>
</tr>
<tr>
<td>中科医疗科技（SHSE:688108）</td>
<td>CN¥21.89</td>
<td>CN¥43.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>PeptiDream（TSE:4587）</td>
<td>¥1738.00</td>
<td>¥3437.58</td>
<td>49.4%</td>
</tr>
<tr>
<td>Kuraray（TSE:3405）</td>
<td>¥1619.00</td>
<td>¥3157.04</td>
<td>48.7%</td>
</tr>
<tr>
<td>Fositek（TWSE:6805）</td>
<td>NT$1405.00</td>
<td>NT$2741.10</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS（TSE:7085）</td>
<td>¥797.00</td>
<td>¥1580.29</td>
<td>49.6%</td>
</tr>
<tr>
<td>ASE 科技控股（TWSE:3711）</td>
<td>NT$275.00</td>
<td>NT$540.37</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology（TWSE:6533）</td>
<td>NT$247.00</td>
<td>NT$481.04</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们基于现金流的 261 只被低估亚洲股票的完整列表。</p>
<p>以下是筛选器中一些选择的预览。</p>
<h2>南京领先生物实验室（SEHK:9887）</h2>
<p><strong>概述：</strong> 南京领先生物实验室有限公司是一家临床阶段的生物技术公司，专注于全球新型抗体药物的研究、开发和商业化，市值为 HK$111.4 亿。</p>
<p><strong>运营：</strong> 南京领先生物实验室有限公司主要通过全球范围内创新抗体药物的研究、开发和商业化来产生收入。</p>
<p><strong>公允价值折扣估算：</strong> 25.7%</p>
<p>南京领先生物实验室的交易价格为 HK$56，低于其估算的公允价值 HK$75.33，表明基于现金流的低估。公司预计在三年内实现盈利，年预测收益增长为 40.72%，年收入增长为 55.8%，超过香港市场平均水平。近期的合作和临床进展增强了其应对自身免疫疾病的潜力，进一步支持其在持续产品开发和高达 10 亿美元的战略合作伙伴关系中的财务前景。</p>
<ul>
<li>根据我们最近的增长报告，南京领先生物实验室的财务表现可能会超过当前水平。</li>
<li>点击这里了解南京领先生物实验室的详细财务健康报告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd862d05-a4c6-494f-bbcf-5b9a803ad2dd/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd862d05-a4c6-494f-bbcf-5b9a803ad2dd/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:9887 截至 2026 年 1 月的折现现金流</p>
<h2>中科医疗科技（SHSE:688108）</h2>
<p><strong>概述：</strong> 中科医疗科技股份有限公司是一家中国医疗器械公司，专注于介入医疗器械的研究、开发、生产和分销，市值约为 CN¥91.1 亿。</p>
<p><strong>运营：</strong> 公司的收入主要来自其医疗产品部门，产生了 CN¥5.0411 亿的收入。</p>
<p><strong>公允价值折扣估算：</strong> 49.6%</p>
<p>中科医疗科技的交易价格为 CN¥21.89，显著低于其估算的公允价值 CN¥43.45，突显出基于现金流的低估。公司最近实现盈利，2025 年 9 月止的九个月内净收入为 CNY 2112 万，扭转了之前的亏损。预计未来三年内收益将大幅增长，年增长率为 63.5%，超过中国市场的平均增长率，尽管股价波动和低预测股本回报率，但仍支持其投资吸引力。</p>
<ul>
<li>我们的增长报告显示，中科医疗科技可能正处于改善前景的阶段。</li>
<li>点击这里访问我们的完整资产负债表健康报告，以了解中科医疗科技的动态。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4dcbc027-94ee-4d25-a685-860056d22101/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4dcbc027-94ee-4d25-a685-860056d22101/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688108 截至 2026 年 1 月的折现现金流</p>
<h2>深圳新威光掩膜制造（SHSE:688401）</h2>
<p><strong>概述：</strong> 深圳新威光掩膜制造有限公司是一家专注于中国掩膜产品设计、开发和生产的光刻公司，市值为 CN¥104.7 亿。</p>
<p><strong>运营：</strong> 公司的收入主要来自其电子元件及零部件部门，总计 CN¥11 亿。</p>
<p><strong>公允价值折扣估算：</strong> 31.5%</p>
<p>深圳新威光掩膜制造的价格为 CN¥54.7，交易价格低于其估算的公允价值 CN¥79.83，表明基于现金流的低估。公司过去一年收益增长了 49.6%，截至 2025 年 9 月的九个月内净收入达到 CNY 171.76 万。尽管股价波动和自由现金流的低股息覆盖率，但未来收入和收益预计将显著高于市场平均水平，增强其投资前景。</p>
<ul>
<li>我们精心准备的深圳新威光掩膜制造增长报告暗示其未来财务前景可能比近期结果更强。</li>
<li>在这份财务健康报告中解锁我们对深圳新威光掩膜制造股票分析的全面见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8d1cc564-fd39-47ce-af9c-a903bd68d5b8/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8d1cc564-fd39-47ce-af9c-a903bd68d5b8/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688401 截至 2026 年 1 月的折现现金流</p>
<h2>总结</h2>
<ul>
<li>点击此链接深入了解我们基于现金流的被低估亚洲股票筛选器中的 261 家公司。</li>
<li>是这些公司的股东吗？确保您不会被突发情况所困扰，通过在 Simply Wall St 中添加您的投资组合，以便及时获得重大股票动态的提醒。</li>
<li>Simply Wall St 是一款为长期股票投资者设计的革命性应用程序，免费且覆盖全球所有市场。</li>
</ul>
<h2>准备好尝试不同的方法了吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠收入来源的稳健分红股来分散您的投资组合，以应对潜在的市场波动。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

泽璟制药-U

<p>随着全球市场表现参差不齐，投资者正将目光投向被低估的亚洲股票。值得注意的包括吴晓波 XDC 开曼、Visional 和苏州泽璟制药，公允价值的折扣高达 49.9%。南京领航生物实验室和中科医疗科技等公司因其增长潜力而受到关注，预计将实现显著的盈利增长。文章强调在当前市场环境下投资这些被低估股票的战略优势，暗示随着市场的稳定，可能会带来可观的回报</p>

<p>As global markets experience mixed performances, with Japan's stock markets declining and China's manufacturing sector showing modest improvement, investors are increasingly turning their attention to the potential opportunities within Asian equities. In this environment, identifying undervalued stocks can be a strategic move, as these investments may offer significant upside potential when market conditions stabilize or improve.</p>
<div class="lb-trans"><p>随着全球市场表现不一，日本股市下跌，而中国制造业部门显示出适度改善，投资者越来越关注亚洲股票中的潜在机会。在这种环境下，识别被低估的股票可以是一项战略性举措，因为这些投资在市场条件稳定或改善时可能提供显著的上行潜力。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基于现金流的亚洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>WuXi XDC Cayman (SEHK:2268)</td>
<td>HK$68.50</td>
<td>HK$135.26</td>
<td>49.4%</td>
</tr>
<tr>
<td>Visional (TSE:4194)</td>
<td>¥10040.00</td>
<td>¥19790.82</td>
<td>49.3%</td>
</tr>
<tr>
<td>Suzhou Zelgen Biopharmaceuticals (SHSE:688266)</td>
<td>CN¥99.90</td>
<td>CN¥199.49</td>
<td>49.9%</td>
</tr>
<tr>
<td>Sino Medical Sciences Technology (SHSE:688108)</td>
<td>CN¥21.89</td>
<td>CN¥43.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>PeptiDream (TSE:4587)</td>
<td>¥1738.00</td>
<td>¥3437.58</td>
<td>49.4%</td>
</tr>
<tr>
<td>Kuraray (TSE:3405)</td>
<td>¥1619.00</td>
<td>¥3157.04</td>
<td>48.7%</td>
</tr>
<tr>
<td>Fositek (TWSE:6805)</td>
<td>NT$1405.00</td>
<td>NT$2741.10</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥797.00</td>
<td>¥1580.29</td>
<td>49.6%</td>
</tr>
<tr>
<td>ASE Technology Holding (TWSE:3711)</td>
<td>NT$275.00</td>
<td>NT$540.37</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology (TWSE:6533)</td>
<td>NT$247.00</td>
<td>NT$481.04</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>药明 XDC 开曼（SEHK:2268）</td>
<td>HK$68.50</td>
<td>HK$135.26</td>
<td>49.4%</td>
</tr>
<tr>
<td>Visional（TSE:4194）</td>
<td>¥10040.00</td>
<td>¥19790.82</td>
<td>49.3%</td>
</tr>
<tr>
<td>苏州泽璟生物制药（SHSE:688266）</td>
<td>CN¥99.90</td>
<td>CN¥199.49</td>
<td>49.9%</td>
</tr>
<tr>
<td>中科医疗科技（SHSE:688108）</td>
<td>CN¥21.89</td>
<td>CN¥43.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>PeptiDream（TSE:4587）</td>
<td>¥1738.00</td>
<td>¥3437.58</td>
<td>49.4%</td>
</tr>
<tr>
<td>Kuraray（TSE:3405）</td>
<td>¥1619.00</td>
<td>¥3157.04</td>
<td>48.7%</td>
</tr>
<tr>
<td>Fositek（TWSE:6805）</td>
<td>NT$1405.00</td>
<td>NT$2741.10</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS（TSE:7085）</td>
<td>¥797.00</td>
<td>¥1580.29</td>
<td>49.6%</td>
</tr>
<tr>
<td>ASE 科技控股（TWSE:3711）</td>
<td>NT$275.00</td>
<td>NT$540.37</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology（TWSE:6533）</td>
<td>NT$247.00</td>
<td>NT$481.04</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 261 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>点击这里查看我们基于现金流的 261 只被低估亚洲股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是筛选器中一些选择的预览。</p>
</div><h2>Nanjing Leads Biolabs (SEHK:9887)</h2>
<div class="lb-trans"><h2>南京领先生物实验室（SEHK:9887）</h2>
</div><p><strong>Overview:</strong> Nanjing Leads Biolabs Co., Ltd. is a clinical-stage biotechnology company focused on the research, development, and commercialization of novel antibody drugs globally, with a market cap of HK$11.14 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 南京领先生物实验室有限公司是一家临床阶段的生物技术公司，专注于全球新型抗体药物的研究、开发和商业化，市值为 HK$111.4 亿。</p>
</div><p><strong>Operations:</strong> Nanjing Leads Biolabs Co., Ltd. generates its revenue primarily through the research, development, and commercialization of innovative antibody drugs on a global scale.</p>
<div class="lb-trans"><p><strong>运营：</strong> 南京领先生物实验室有限公司主要通过全球范围内创新抗体药物的研究、开发和商业化来产生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 25.7%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 25.7%</p>
</div><p>Nanjing Leads Biolabs is trading at HK$56, below its estimated fair value of HK$75.33, suggesting undervaluation based on cash flows. The company anticipates becoming profitable in three years with forecasted earnings growth of 40.72% annually and revenue growth of 55.8% per year, surpassing the Hong Kong market average. Recent collaborations and clinical advancements enhance its potential for addressing autoimmune diseases, further supporting its financial outlook amidst ongoing product developments and strategic partnerships valued up to $1 billion.</p>
<div class="lb-trans"><p>南京领先生物实验室的交易价格为 HK$56，低于其估算的公允价值 HK$75.33，表明基于现金流的低估。公司预计在三年内实现盈利，年预测收益增长为 40.72%，年收入增长为 55.8%，超过香港市场平均水平。近期的合作和临床进展增强了其应对自身免疫疾病的潜力，进一步支持其在持续产品开发和高达 10 亿美元的战略合作伙伴关系中的财务前景。</p>
</div><ul>
<li>In light of our recent growth report, it seems possible that Nanjing Leads Biolabs' financial performance will exceed current levels.</li>
<li>Click here to discover the nuances of Nanjing Leads Biolabs with our detailed financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>根据我们最近的增长报告，南京领先生物实验室的财务表现可能会超过当前水平。</li>
<li>点击这里了解南京领先生物实验室的详细财务健康报告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd862d05-a4c6-494f-bbcf-5b9a803ad2dd/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/bd862d05-a4c6-494f-bbcf-5b9a803ad2dd/chart/dcf?theme=light"/></p>
<p>SEHK:9887 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SEHK:9887 截至 2026 年 1 月的折现现金流</p>
</div><h2>Sino Medical Sciences Technology (SHSE:688108)</h2>
<div class="lb-trans"><h2>中科医疗科技（SHSE:688108）</h2>
</div><p><strong>Overview:</strong> Sino Medical Sciences Technology Inc. is a Chinese medical device company focused on the research, development, production, and distribution of interventional medical devices, with a market cap of approximately CN¥9.11 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 中科医疗科技股份有限公司是一家中国医疗器械公司，专注于介入医疗器械的研究、开发、生产和分销，市值约为 CN¥91.1 亿。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its medical products segment, which generated CN¥504.11 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其医疗产品部门，产生了 CN¥5.0411 亿的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 49.6%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 49.6%</p>
</div><p>Sino Medical Sciences Technology is trading at CN¥21.89, significantly below its estimated fair value of CN¥43.45, highlighting undervaluation based on cash flows. The company recently turned profitable with a net income of CNY 21.12 million for the nine months ending September 2025, reversing a prior loss. Earnings are projected to grow substantially at 63.5% annually over the next three years, outpacing the Chinese market average growth rate and supporting its investment appeal despite share price volatility and low forecasted return on equity.</p>
<div class="lb-trans"><p>中科医疗科技的交易价格为 CN¥21.89，显著低于其估算的公允价值 CN¥43.45，突显出基于现金流的低估。公司最近实现盈利，2025 年 9 月止的九个月内净收入为 CNY 2112 万，扭转了之前的亏损。预计未来三年内收益将大幅增长，年增长率为 63.5%，超过中国市场的平均增长率，尽管股价波动和低预测股本回报率，但仍支持其投资吸引力。</p>
</div><ul>
<li>Our growth report here indicates Sino Medical Sciences Technology may be poised for an improving outlook.</li>
<li>Click here and access our complete balance sheet health report to understand the dynamics of Sino Medical Sciences Technology.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们的增长报告显示，中科医疗科技可能正处于改善前景的阶段。</li>
<li>点击这里访问我们的完整资产负债表健康报告，以了解中科医疗科技的动态。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4dcbc027-94ee-4d25-a685-860056d22101/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/4dcbc027-94ee-4d25-a685-860056d22101/chart/dcf?theme=light"/></p>
<p>SHSE:688108 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:688108 截至 2026 年 1 月的折现现金流</p>
</div><h2>Shenzhen Newway Photomask Making (SHSE:688401)</h2>
<div class="lb-trans"><h2>深圳新威光掩膜制造（SHSE:688401）</h2>
</div><p><strong>Overview:</strong> Shenzhen Newway Photomask Making Co., Ltd is a lithography company focused on the design, development, and production of mask products in China with a market cap of CN¥10.47 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 深圳新威光掩膜制造有限公司是一家专注于中国掩膜产品设计、开发和生产的光刻公司，市值为 CN¥104.7 亿。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Electronic Components &amp; Parts segment, totaling CN¥1.10 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其电子元件及零部件部门，总计 CN¥11 亿。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 31.5%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 31.5%</p>
</div><p>Shenzhen Newway Photomask Making, priced at CN¥54.7, is trading 31.5% below its estimated fair value of CN¥79.83, indicating undervaluation based on cash flows. The company's earnings grew by 49.6% over the past year with net income reaching CNY 171.76 million for the nine months ending September 2025. Despite share price volatility and a low dividend coverage by free cash flow, future revenue and earnings are forecast to grow significantly above market averages, enhancing its investment prospects.</p>
<div class="lb-trans"><p>深圳新威光掩膜制造的价格为 CN¥54.7，交易价格低于其估算的公允价值 CN¥79.83，表明基于现金流的低估。公司过去一年收益增长了 49.6%，截至 2025 年 9 月的九个月内净收入达到 CNY 171.76 万。尽管股价波动和自由现金流的低股息覆盖率，但未来收入和收益预计将显著高于市场平均水平，增强其投资前景。</p>
</div><ul>
<li>Our expertly prepared growth report on Shenzhen Newway Photomask Making implies its future financial outlook may be stronger than recent results.</li>
<li>Unlock comprehensive insights into our analysis of Shenzhen Newway Photomask Making stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们精心准备的深圳新威光掩膜制造增长报告暗示其未来财务前景可能比近期结果更强。</li>
<li>在这份财务健康报告中解锁我们对深圳新威光掩膜制造股票分析的全面见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8d1cc564-fd39-47ce-af9c-a903bd68d5b8/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/8d1cc564-fd39-47ce-af9c-a903bd68d5b8/chart/dcf?theme=light"/></p>
<p>SHSE:688401 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:688401 截至 2026 年 1 月的折现现金流</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Click this link to deep-dive into the 261 companies within our Undervalued Asian Stocks Based On Cash Flows screener.</li>
<li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li>
<li>Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击此链接深入了解我们基于现金流的被低估亚洲股票筛选器中的 261 家公司。</li>
<li>是这些公司的股东吗？确保您不会被突发情况所困扰，通过在 Simply Wall St 中添加您的投资组合，以便及时获得重大股票动态的提醒。</li>
<li>Simply Wall St 是一款为长期股票投资者设计的革命性应用程序，免费且覆盖全球所有市场。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>准备好尝试不同的方法了吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠收入来源的稳健分红股来分散您的投资组合，以应对潜在的市场波动。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

3 只亚洲股票被认为低估了高达 49.6%